• 新闻与活动

    学术成果

Optimal Designs for Pairwise Calculation: an Application to Free Energy Perturbation in Minimizing Prediction Variability

January 30, 2020 Pages 247-257

Pairwise-based methods such as the free energy perturbation (FEP) method have been widely deployed to compute the binding free energy differences between two similar host–guest complexes. The calculated pairwise free energy difference is either directly adopted or transformed to absolute binding free energy for molecule rank ordering. We investigated, through both analytic derivations and simulations, how the selection of pairs in the experiment could impact the overall prediction precision. Our studies showed that (1) the estimated absolute binding free energy (urn:x-wiley:01928651:media:jcc26095:jcc26095-math-0001) derived from calculated pairwise differences (ΔΔG) through weighted least squares fitting is more precise in prediction than the pairwise difference values when the number of pairs is more than the number of ligands and (2) prediction precision is influenced by both the total number of pairs and the specifically selected pairs, the latter being critically important when the number of calculated pairs is limited. Furthermore, we applied optimal experimental design in pair selection and found that the optimally selected pairs can outperform randomly selected pairs in prediction precision. In an illustrative example, we showed that, upon weighing ligand structure similarity into design optimization, the weighted optimal designs are more efficient than the literature reported designs. This work provides a new approach to assess retrospective pairwise-based prediction results, and a method to design new prospective pairwise-based experiments for molecular lead optimization. © 2019 Wiley Periodicals, Inc.

想继续了解更多?

联系我们

我们期待您的留言

让我们知道如何为您提供帮助,我们团队将24小时内与您联系!

姓名
电话
邮箱
国家/地区
北京市
天津市
上海市
重庆市
河北省
山西省
辽宁省
吉林省
黑龙江省
江苏省
浙江省
安徽省
福建省
江西省
山东省
河南省
湖北省
湖南省
广东省
海南省
四川省
贵州省
云南省
陕西省
甘肃省
青海省
台湾省
内蒙古自治区
广西壮族自治区
西藏自治区
宁夏回族自治区
新疆维吾尔自治区
香港特别行政区
澳门特别行政区
从事行业
小分子药物研发
抗体药物研发
CRO/CDMO
投融资机构
高校/研究院所/医院
园区
生物医药产业
感兴趣的业务
小分子药物发现
抗体药物发现
药物固体形态研发
化学合成服务(含自动化合成)
实验室自动化解决方案
所在公司
是否需要业务人员跟进?
暂不需要
验证码

我已阅读并同意 晶泰科技隐私政策法律声明